Description

The Pancreatic Cancer Gene & Antigen Risk Blood Panel is used to assess genetic risk factors and tumor markers associated with pancreatic cancer. This panel helps in the diagnosis and treatment planning for individuals at risk or suspected of having pancreatic cancer.

Tests Included:

BRCA1 and BRCA2:

  • These are tumor suppressor genes that, when mutated, increase the risk of several cancers, including pancreatic cancer.
  • Mutations in these genes can be inherited and significantly raise an individual's lifetime risk for pancreatic cancer, especially in those with a family history of breast, ovarian, or pancreatic cancers.

CDKN2A:

  • This gene encodes a protein involved in cell cycle regulation. Mutations in CDKN2A are associated with an increased risk of pancreatic cancer, particularly in families with a history of this disease.
  • CDKN2A mutations are found in some familial pancreatic cancer cases.

CA19-9:

  • This is a tumor marker specific to pancreatic cancer.
  • Elevated levels of CA19-9 in the blood can indicate the presence of pancreatic cancer, though it is not specific to this condition alone. It can also be elevated in other conditions like liver disease, gallstones, and gastrointestinal issues.
  • CA19-9 is often used to monitor the treatment response and detect recurrence of pancreatic cancer.

Purpose of the Panel:

  • Diagnosing Pancreatic Cancer: By evaluating both genetic mutations and antigen levels (CA19-9), this panel can aid in confirming the presence of pancreatic cancer.
  • Identifying Genetic Risk: The genetic tests (BRCA1, BRCA2, and CDKN2A) help determine an individual’s inherited risk for pancreatic cancer, providing valuable information for both early detection and preventive measures.
  • Treatment and Monitoring: The CA19-9 marker is used for tracking treatment efficacy and detecting cancer recurrence after surgery or other treatments.

Test Details:

  • Fasting: Not required for this blood test.
  • Implications: The results can help guide discussions with a healthcare provider regarding genetic counseling, surveillance strategies, and treatment options.

This blood panel is an important tool for individuals at higher risk of pancreatic cancer, allowing for earlier detection, better management, and more informed treatment choices.